CS Paper Radar

LUCAID: Agentic Multimodal AI for Lung Cancer Precision Pathology

Marie-Lisa Eich, Kai Standvoss, Timo Milbich, Alexander Möllers, Miriam Hägele, Philipp Anders, Lars Tharun, Hanna Kontradiuk, Sebastian Kons, Nader Aldoj, Recepcan Adigüzel, Adam Narai, Lukas Hönig, Jonathan Striebel, Binru Yang, Mihnea P. Dragomir, Marvin Sextro, Philipp Keyl, Philipp Jurmeister, Rosemarie Krupar, Evelyn Ramberger, James Wells, Julika Ribbat-Idel, Andreas Kunft, Hussam Shuaib, Christian Grohé, Reinhard Büttner, David Horst, Klaus-Robert Müller, Lukas Ruff, Maximilian Alber, Frederick Klauschen, Simon Schallenberg

cs.CV cs.AIcs.LG ·submitted 2026-08-24 20:07 UTC · v2

Abstract

Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological assessment remains largely visual and semi-quantitative and shows interobserver variability, while existing artificial intelligence (AI) tools cover only selected tasks, rarely reach generalizable expert-level performance, and lack prospective clinical validation. To address these challenges, we developed and clinically validated LUCAID, an agentic AI system for precision lung cancer pathology. An integrative agent couples diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive biomarker scoring (PD-L1, MET, TROP-2) to automated structured report generation. LUCAID enables users to interactively query the module outputs and generate reports that contextualize the results. Against large-scale expert ground-truth annotations, the analysis modules achieved F1 scores of 0.82-0.95. In prospective clinical validation, LUCAID reached 93.0% concordance with an expert-panel adjudicated reference standard across clinically actionable decisions, compared with 68.3-81.1% for five experienced thoracic pathologists.

Closest papers

Nearest neighbours by meaning across the whole index.

LUCQUE: A lung cancer screening dataset from Québec for reliable AI evaluation

cs.DB cs.AI ·2026-11-09 ·Johanna Topalis, Yannick Lemaréchal, Gabriel Couture, Hanife Ersay, Loran Nas +5 more
similarity 0.75
Abstract

BACKGROUND: AI-based tools are expected to play a key role in lung cancer screening (LCS). The evaluation of these tools often relied on private datasets or fragmented public datasets with inconsistent availability of clinical data and expert nodule annotations. This has hindered reproducibility, comparability, and independent assessment of AI tools. To address these gaps, we present LUCQUE, a novel, large, comprehensively annotated dataset derived from LDCT lung cancer screening in Québec, which is accessible for reliable AI evaluation. METHODS: LUCQUE was curated and is hosted on PARADIM, a digital infrastructure supporting DICOM data de-identification, annotation, long-term storage and analysis. LDCT scans and clinical information were combined to a curated collection and complemented by voxel-level, expert-derived pulmonary nodule and cyst segmentations, and Lung-RADS-based lesion characteristics. Key dataset characteristics and statistics were reported, including participant demographics, imaging parameters, radiological findings, and segmented lesion characteristics. Dataset analyses were conducted according to PARADIM's model-to-data approach, in which user code is executed on the platform such that data remains on premise. RESULTS: LUCQUE currently comprises 1,678 LDCT baseline studies from 1,678 participants. Most studies were classified as Lung-RADS 2. A total of 1,776 pulmonary nodules and 60 cysts were annotated, with a median (interquartile range) volume of $89\,(56,\,159)\,\mathrm{mm}^3$ and $1,384\,(589,\,3793)\,\mathrm{mm}^3$ respectively. CONCLUSIONS: Compared to publicly available LCS datasets, LUCQUE currently represents the largest accessible annotated real-world LCS dataset. Access to LUCQUE is provided via a model-to-data approach, enabling privacy-preserving, reproducible, and independent real-world evaluation of AI tools in LCS.

0.21

Disentangling Lung-Cancer CT/LDCT AI: A Systematic Evidence Map of Clinical Tasks, Evidence Chains, and Translational Gaps

cs.LG ·2026-09-28 ·Surajit Das
similarity 0.72
Abstract

Artificial-intelligence studies using computed tomography (CT) for lung cancer are often broadly labelled "prediction" despite addressing clinically distinct tasks. We systematically mapped CT/low-dose CT (LDCT)-centered lung-cancer AI using five-database retrieval, full-text eligibility assessment, role-aware modality/omics extraction, clinical-task classification, and a Multi-Tier Evidence Graph (MTEG). The final corpus comprised 293 studies (2016-2026): 230 Detection, 8 future Risk-prediction, and 55 Other studies. Clinical variables (96.2%), 3D CT/LDCT (73.0%), and radiomics (63.5%) predominated, whereas external validation (29.0%), calibration (20.5%), decision-curve analysis (13.0%), longitudinal CT (17.7%), and saliency/attribution XAI (21.5%) were less frequent. The MTEG comprised 377 nodes and 3,444 edges; only 31 studies (10.6%) completed the six-tier substantive evidence chain, with greatest attrition at reasoning/explanation. Overall, the literature is detection-dominated, genuine future risk prediction remains uncommon, and complete translational evidence chains are rare.

0.08

Responsible Integration of AI in Cancer Genomics: Barriers, Risks, and Pathways to Trustworthy Clinical Translation

cs.AI cs.CL ·2026-08-31 ·Bahar İlgen, Yiannos Tolias, Denise Kühnert, Paraskevi Papadopoulou, Magnus Westerlund +3 more
similarity 0.68
Abstract · Review article

Artificial intelligence (AI) and natural language processing (NLP) are increasingly used to extract, integrate, and interpret biomedical knowledge relevant to cancer genomics, yet their translation into routine clinical oncology has been comparatively slow. The central challenge is not computational capability alone, but trustworthy integration into clinical workflows. This review examines how NLP and AI support the cancer genomics pipeline, from literature mining and automated variant interpretation to clinical trial matching, knowledge graph construction, and multimodal data integration. We identify four interrelated translational failure domains: evidence inconsistency, explainability and uncertainty, data governance and reproducibility, and interoperability. Rather than considering these challenges in isolation, we take a systems-level view, focusing on their interaction across the translational pathway. We propose a conceptual framework and roadmap for addressing these domains through rigorous validation, uncertainty-aware methods, interoperable infrastructures, regulatory alignment, and human oversight across the AI lifecycle. Progress toward routine clinical use will depend less on further improving model capability than on systematically addressing these interacting failure domains from development through deployment and post-deployment monitoring.

0.12

An Agentic AI Workflow for Liver Lesion Segmentation and Structured Radiology Reporting

cs.CV cs.LG ·2026-10-25 ·Fatma Ahmed Mansour, Rahatara Ferdousi, Zyad Medhat Mahmoud Ashor, Manar Fathy Elshenawy, Ibrahim Shehaby +2 more
similarity 0.67
Abstract

Despite advances in automated liver lesion segmentation, a gap remains between image-derived predictions and clinically interpretable radiology reports. Bridging this gap requires quantitative measurements that are both reproducible and traceable. We present an evidence-grounded agentic AI framework that connects liver and lesion segmentation with deterministic quantification and structured reporting. TotalSegmentator-based nnU-Net models delineate the liver, Couinaud segments, and lesions, while computational tools extract volumes, dimensions, counts, and anatomical locations. A large language model (LLM) organizes these measurements into a predefined reporting schema, with numerical consistency checks against source measurements. On 51 LiTS cases, the segmentation stage achieved a liver Dice score of 0.947, lesion sensitivity of 75.6%, and positive predictive value of 68.9%. Exploratory screening of 25,494 MERLIN reports identified 10,208 (40.0%) with liver-related abnormalities. By connecting quantitative imaging evidence with agentic report generation, this work takes a step toward human-centered medical AI that prioritizes traceability and clinical relevance.

0.23

MedPAO-VL: Interpretable and Protocol-Compliant Agent for Structured Radiology Report Generation

cs.CV ·2026-10-15 ·Shrish Shrinath Vaidya, Gowthamaan Palani, Minmini Selvam, Gokulraja Srinivasaraja, Ganapathy Krishnamurthi
published similarity 0.66
Abstract · The paper has been accepted at ECCV BISCUIT Workshop, 2026

Despite the remarkable generalization capabilities of Large Language Models, generating clinically accurate and structured radiology reports from medical images remains a significant challenge. Current end-to-end approaches function as black boxes, prone to factual hallucinations and generating ungrounded findings. This lack of reliability and failure to adhere to domain-specific structuring protocols, fundamentally limits their clinical utility. We present MedPAO-VL, a multimodal agent that shifts the paradigm from monolithic generation to explainable, iterative, protocol-compliant structured report generation. Unlike deterministic models, our plan-act-observe loop functions as a goal-oriented agent: it first perceives the Chest X-Ray through an explainable vision module designed to capture inherent diagnostic uncertainty, then iteratively refines the generated report by observing semantic discrepancies and self-correcting its generation for better alignment with visually detected clinical findings. Evaluation of our framework demonstrates that this agentic reasoning improves clinical correctness and completeness, achieving an expert-rated accuracy score of 3.5/5 and a structural score of 4.3/5. By prioritizing pathology specific explainability and iterative refinement over opaque end-to-end mapping, MedPAO-VL offers a transparent and clinically viable alternative for automated structured radiology report generation.

0.22

Explainable Artificial Intelligence (XAI) in Computational Pathology: Definitions, Taxonomy, and Recommendations

cs.AI cs.CV ·2026-08-28 ·Shubham Innani, Suhang You, Adam Shephard, Bhakti Baheti, Francesco Ciompi +11 more
published similarity 0.66
Abstract · On behalf of MICCAI SIG-CompPath. More information: https://miccai.org/index.php/special-interest-groups/sig-comppath/

Computational pathology (CompPath) is transforming medicine by leveraging artificial intelligence (AI) algorithms to support diagnosis, prognosis, and treatment prediction from gigapixel whole-slide images. Clinical adoption is progressing, but is constrained by concerns about safety, accountability, and regulatory oversight in high-stakes clinical environments. Explainable AI (XAI) systems hold promise for building trust and enabling verification, yet the literature remains fragmented due to inconsistent terminology, overlapping methodological families, ad hoc validation, and current reviews. This review aims to formalize XAI methods in CompPath through the: i) introduction of a pathology-centric vocabulary comprising seven core terms; ii) development of a taxonomy across methodological families and three orthogonal axes (stage, type, scope); and iii) establishment of a task-driven framework that maps five clinical questions to recommended methods, method evaluation, and deployment context. Five key gaps between current XAI capabilities and clinical deployment are identified, and actionable steps are proposed to advance XAI for CompPath.

0.42

OpenMTB-Audit: Exposing Over-Refusal and Clinical Expert Perspectives in LLM-Based Molecular Tumor Board Safety Evaluation

cs.AI cs.LG ·2026-10-01 ·Negin Ashrafi, Jia Luo, Stacey M. Frumm, Roxana Daneshjou
publishedbenchmarkcode/data similarity 0.66
Abstract · Accepted for oral presentation and publication at the Pacific Symposium on Biocomputing (PSB) 2027

Molecular tumor boards integrate genomic findings, clinical context, and therapeutic evidence to support precision oncology. As AI enters this workflow, a key safety challenge is distinguishing truly unsupported recommendations from evidence-supported options that still require oncologist review because of incomplete information, poor ECOG performance status, or other clinical caveats. We introduce OpenMTB-Audit, an open-source benchmark of 500 synthetic non-small cell lung cancer cases spanning five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. Across eight large language model configurations, we identify pervasive over-refusal: all LLM configurations failed to retain the Partially Supported label in 83.3-100% of true Partially Supported cases, achieving high aggregate safety scores through label collapse rather than clinically calibrated reasoning. To address this limitation, we developed MTB-AuditAgent, a deterministic seven-module framework separating evidence verification, missing-information detection, safety classification, and abstention. It reduces over-refusal to 6.7% and achieves 91.2% accuracy (95% CI: 88.6-93.6%). A two-oncologist annotation study found disagreement concentrated at the boundary between information sufficiency and treatment optimization, underscoring the need to preserve clinically meaningful distinctions.

0.56

Advancing Clinical Genomic Analysis with a Skill-Centred Agent

cs.AI q-bio.GN ·2026-10-29 ·Qiaoyu Zheng, Weike Zhao, Yanjie Fan, Ye Cao, Mengqi Jiang +8 more
benchmark similarity 0.65
Abstract

Clinical genomic analysis requires experts to integrate evolving guidelines, databases, and computational evidence. As sequencing has become increasingly accessible, this complex and labor-intensive process has become a major bottleneck to the timely use of genomic information in clinical decision-making. To fill this gap, we developed ClinGeX, a large-language-model agent that composes 105 curated executable skills through task-specific retrieval and dependency-aware orchestration. On 223 temporally held-out benchmark cases, ClinGeX achieved 71.7\% macro-averaged task-level concordance with expert reference classifications, compared with 45.7\% for the strongest comparator. In a three-condition, counterbalanced human-AI collaboration study, 45 clinical genomic professionals assessed 135 clinically derived cases under routine (no AI assistance), DeepSeek-assisted and ClinGeX-assisted conditions. ClinGeX assistance increased raw case-level concordance across criterion-level variant analysis, genomic interpretation in rare disease and molecular oncology decision-making (51.1\%, 57.8\%, 64.4\% versus 15.6\%, 31.1\%, 20.0\% in comparator conditions) and reduced reported interpretation time in all scenarios. During an exploratory one-month real-world non-interventional assessment, 11 experienced professionals submitted feedback on 96 self-selected analysis episodes and reported frequent conclusion adoption and time savings. These findings support executable domain skills as a promising approach to augment specialist genomic interpretation.

0.23